Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Rivastigmine patches	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA
Roflumilast (Daxas)	TA461 - Roflumilast for treating chronic obstructive pulmonary disease	To be use in line with NICE. Supported with a RICaD
Ropinirole M/R tablets		ESCA for Parkinson's disease
Ropinirole tablets		ESCA for restless legs
Rotigotine patches		Specialist initiation and stabilisation, ESCA
Rufinamide tablets		ESCA
Sacubitril/Valsartan (Entresto®)	TA388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction	RICaD. Transfer to primary care at three months following initiation by Heart Failure specialist supported by a RICaD.
Salofalk foam enema
Salofalk granules
Sandocal effervescent tablets

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.